EyePoint, Inc. (NASDAQ: EYPT), which is engaged in the development of therapeutics for retinal diseases, on Wednesday announced financial results for the fourth quarter of fiscal 2025, reporting lower revenues and a wider net loss.
- Fourth-quarter net revenue declined sharply to $0.6 million from $11.6 million in the corresponding quarter last year
- Net product revenue for the quarter was $0.3 million, compared to $0.8 million in the year-ago quarter
- Q4 revenue from license and royalties declined to $0.3 million from $10.8 million in the prior-year quarter
- The company reported a net loss of $67.6 million or $0.81 per share for the fourth quarter, versus a loss of $41.4 million or $0.64 per share last year
- Operating expenses increased sharply to $71.0 million in Q4 from $56.8 million in the same period last year
- Net non-operating income totaled $2.9 million
- EyePoint appointed Michael Campbell as chief commercial officer; Campbell assumes responsibility for commercial strategy and launch readiness for DURAVYU
- It expanded intellectual property protection for the DURAVYU insert formulation with the issuance of a US patent last month